^
    Back
    Association details:
    Biomarker:HR negative + BRCA1 mutation
    Cancer:HER2 Negative Breast Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    11/24/2021
    Excerpt:
    SYSTEMIC ADJUVANT TREATMENT: HR-NEGATIVE - HER2-NEGATIVE DISEASE...Addition of 1 year of adjuvant olaparib is an option for select patients with germline BRCA1/2 mutation after completion of adjuvant chemotherapy.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2020
    Title:

    176P - Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332)

    Published date:
    09/14/2020
    Excerpt:
    Regardless of the treatment arm, pCR rates were higher in HR- than in HR+ pts (57.9%, 44/76 vs. 41.4%, 12/29;). We observed highest pCR rates in HR- pts with BRCA1/2 mutations (65.8%, 25/38) and lowest in HR+ pts without BRCA1/2 mutations (0%, 0/8).
    Secondary therapy:
    paclitaxel
    Trial ID:
    GeparOla